Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications

IN BRIEF Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liragl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysham, Carol H., Campos, Carlos, Kruger, Davida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2018
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898162/
https://www.ncbi.nlm.nih.gov/pubmed/29686454
http://dx.doi.org/10.2337/cd17-0064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898162/
https://www.ncbi.nlm.nih.gov/pubmed/29686454
http://dx.doi.org/10.2337/cd17-0064

Ejemplares similares